IndustryCompany release

Mesoblast reports US$115M first full-year Ryoncil sales and advances four late-stage programmes

Mesoblast Ltd (MESO) · Tue 17 Nov 2026

Mesoblast says its mesenchymal stromal cell therapy earned US$115M in net revenue in FY2026, as the company progresses trials in back pain, heart failure, GvHD and Duchenne.

Mesoblast reported US$115M in net revenue for its 2026 financial year, the first full year of US sales of Ryoncil. The company describes the product as the only mesenchymal stromal cell therapy approved by the US Food and Drug Administration (FDA). The figures come from its full-year investor presentation.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Mesoblast Ltd ↗

Article written by VigiEye from the official source (Mesoblast Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →